We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.
INTRODUCTION
Allogeneic haematopoietic cell transplantation (HCT) represents a potential cure for AML, but long-term survival is hampered by relapse of leukaemia and TRM. The incidence of AML increases with age, as do comorbidities and frailties. Several studies have reported reduced TRM after HCT with reduced conditioning, but also an increased rate of relapse. [1] [2] [3] Single-centre studies have compared non-myeloablative (NM) and myeloablative (MA) transplants in AML, myelodysplasia (MDS) and ALL patients and found equivalent survival rates, but often with modest separation of the two groups by age. [4] [5] [6] [7] Since 2000, we have used a truly NM regimen primarily relying on the GVL effect for AML patients over 50 years of age. 8 Patients under 50 years received MA, unless significant comorbidity was present, which was the case in less than 10% of eligible patients.
In this retrospective analysis, we report the outcome of 207 consecutive AML patients, receiving allogeneic HCT preceded by either NM or MA conditioning at our institution.
PATIENTS AND METHODS Patients
The study included 207 consecutive adult (X15 years) patients with AML referred to our institution for allogeneic HCT during an 11-year period between January 2000 and December 2010. Before HCT, all patients provided written informed consent to allow exploitation of data.
Diagnosis was established by BM aspiration and biopsy. Cytogenetic risk was assessed according to Grimwade, 9 and cytogenetic data were available in 197 (95%) of the patients. Patient and donor characteristics are given in Table 1 . CR was defined as o5% myeloblasts in BM and no evidence of extramedullary disease. Selection of patients as candidates for allogeneic HCT was done according to the Danish National Guidelines. According to these guidelines, standard and high-risk AML patients in first CR (CR1) are eligible for allogeneic HCT. The primary factor for choosing conditioning was age. Patients aged 50 years or below were selected for MA, unless they previously had received MA conditioning or had significant comorbidity. To minimise individual physician's preferences, 10 selection of conditioning regimen was done at a patient care conference after mutual agreement among the transplant physicians.
Donors
All donors were adult sibling or unrelated register donors. Patients and donors were typed for HLA-A, -B and -C using low-resolution techniques if they were siblings and high-resolution techniques if unrelated. HLA-DRB1 and HLA-DQB1 were analysed with high-resolution techniques in all patients and donors. Matching criteria in the MA group were 10 out of 10 allele match, 9 out of 10 allele match, 8 out of 10 allele match or 1 Ag mismatch. Two allele mismatches were not allowed to be located at the same HLA class. Matching in NM transplants should be HLA-identical siblings or 10 out of 10 or 9 out of 10 allele matched. The donors were generally well matched; a fully matched donor was found in 93% of the MA transplants and in 96% of the NM transplants. All grafts were T-cell replete.
Transplant procedure
In the MA group, 94% of the patients received TBI of 12 Gy administered as 4 Gy on days À 6, À 5 and À 4 plus CY of 60 mg/kg on days À 3 and À 2. The remaining seven patients (6%) in the MA group received i.v. BU of 0.8 mg/kg Â 4 days on -7, À 6, À 5, À 4 days plus CY of 60 mg/kg on days À 3 and À 2. Five patients with Ag mismatched donors received antithymocyte globulin of 2.5 mg/kg on days À 5, À 4 and À 3 as a part of the conditioning. In the NM group, 95% received fludarabine of 30 mg/m 2 on days À 4, À 3, À 2 plus TBI of 2 Gy on day 0. 1 Immunosuppression for MA patients was cyclosporine and short-course MTX, and for NM patients cyclosporine or tacrolimus plus mycophenolate mofetil (MMF). In NM patients with a sibling donor, MMF was stopped at day þ 28, NM patients with an unrelated donor had MMF tapered from day þ 40 to day þ 96. Patients in both groups were planned to stop calcineurin inhibitor 6 months after HCT, unless GVHD was present.
Acute GVHD (aGVHD) was treated with 2 mg/kg of prednisolone with tapering starting after 7-14 days and according to clinical evaluation. Second line treatment for steroid-resistent aGVHD was infliximab and MMF.
All patients in the MA group were isolated in a HEPA-filtered single-bed room from start of chemotherapy until a neutrophil count of 0.5 mia/L in Abbreviations: CR1 ¼ first CR; CR2 ¼ second CR; HCT ¼ haematopoietic cell transplantation; PIF ¼ primary induction failure; pos ¼ positive; neg ¼ negative.
Outcome of MA and NM allogeneic HCT in AML patients H Sengeløv et al peripheral blood was achieved. Patients in the NM group were treated either in the outpatient clinic or in the ward, without any isolation procedure. Infection prophylaxis during the cytopenic post transplant period was fluconazole and piperacillin/tazobactam in MA patients, fluconazole and ciprofloxacin in NM patients. Fifteen (12%) of the MA patients transplanted early in the period received gastrointestinal decontamination and no fluconazole. In all patients, valacyclovir and sulfamethoxazole/trimethoprim were administered while the patients were on immunosuppressive therapy. Measurement of CMV copies in blood was done weekly by PCR until day þ 100 or longer if the patient was on two or more immunosuppressive drugs. All patients were seen in our outpatient transplant clinic during the follow-up period.
Statistical analysis
Data from MA and NM conditioning regimes were described and compared by frequencies and w 2 tests, or means, standard deviations and t-tests. OS was analysed by the Kaplan-Meier method and multivariable Cox regression. The end points TRM, relapse, aGVHD and chronic GVHD (cGVHD) were analysed in competing risks models using the AalenJohansen method and cause-specific multivariable Cox regression. In all multivariable analyses, predictor variables were selected according to results from previous studies, and limitations of the data material. Timevarying variables were not considered as this was not relevant.
RESULTS
In total, 122 patients received MA conditioning and 85 received NM conditioning ( Table 1 ). The MA patients were transplanted at a more advanced disease stage and more often received BM grafts (41% versus 0% in the NM group). More NM patients were smokers (48% versus 30%) and related donors were significantly older, 54 versus 35 years (Po0.001). The median ages in the MA and NM groups were 39 and 59 years, respectively, Po0.001. No difference was observed in terms of Karnofsky performance score (KPS), body mass index, prior MDS, cytogenetic risk, HLA match, CMV Ab match or recipient-donor sex match.
Graft failure was seen in four (3.3%) patients in the MA group and in three (3.5%) patients in the NM group. Of the four MA patients with graft failure, three received a second transplant and one died of infection in neutropenia. All three patients in the NM group were rescued with a second transplant.
OS among the 18 (9%) patients transplanted in primary induction failure or beyond CR2 was short and no difference between the MA and NM patients was found. Median survival time with 96 (62-134) months of observation time in surviving patients was 6.1 months (CI: 1.9-10.3) in MA patients versus 5.2 months (CI: 0-11.2) in NM patients. These data were not analysed further due to the modest number of patients.
Patients in CR1 and CR2 were analysed separately. MA conditioning was administered to 60 patients in CR1 and 50 patients in CR2, whereas 62 patients in CR1 and 17 patients in CR2 were transplanted after NM conditioning ( Table 2) .
Among CR1 patients, graft source in the MA patients was G-CSFmobilised PBSCs (G-PBSCs) in 41 (68%) patients and BM in 19 (32%) patients, whereas all of the NM patients were transplanted with G-PBSCs. Related donors for the MA patients were significantly younger than those for the NM patients, 35.1 years (10-58) versus 53.0 years (32-65), Po0.0001. The two groups were comparable in terms of cytogenetic risk, prior MDS, KPS and recipient-donor sex match and relation. Distribution of graft type in the patients transplanted in CR2 was BM in 26 (52%) and G-PBSC in 24 (48%) of the MA patients, whereas all NM patients in CR2 received G-PBSCs. Related donors for the MA patients were significantly younger than in the NM patients, 34.9 years (28-59) versus 64.3 years (62-67), Po0.0001. As for the CR1 patients, no difference in cytogenetic risk, prior MDS, KPS, donor age and relation was seen in the CR2 patients.
TRM and acute GVHD Among CR1 patients, 13 and 11 patients died from TRM in the MA and NM groups, respectively, whereas among the CR2 Figure 1 . Cumulative incidence (CI) of TRM in CR1 (left) and CR2 patients (right). CI of TRM from myeloablative conditioning is depicted in black line with 95% confidence intervals shaded in dark grey and non-myeloablative conditioning in grey line with 95% confidence intervals shaded in light grey. Death from relapse was used as competing event. (Figure 3 ), respectively. A multiple regression analysis for overall mortality risk factors is shown in Table 3 . Conditioning was not a mortality risk factor in either CR1 or CR2 patients. In CR1 patients, a KPS o90 was a statistically significant risk factor for mortality, HR: 2.54 (CI: 1.04-6.21), P ¼ 0.04, whereas KPS had no influence in CR2 patients.
Conditioning and age were not tested in the same multivariable analysis, as they were dependent variables.
Chronic GVHD The 3-year cumulative incidence of cGVHD in CR1 patients was 52.8% (CI: 39.9-65.8) and 41.9% (CI: 29.3-54.7) in MA and NM patients, respectively ( Figure 5 ). In CR2 patients, the cumulative incidence was 32.7% (CI: 19.0-46.3) and 41.2% (CI: 17.8-64.6), respectively. No difference was observed among the conditioning regimens, either for CR1 or CR2 patients. In a multivariable regression analysis of cGVHD including conditioning, donor relation and patient-donor sex match, no significant risk factor was identified (results not shown).
DISCUSSION
By comparison of MA and NM conditioning in a cohort of AML patients in remission, we found both TRM and relapse rate to be similar resulting in comparable OS despite a 20-year age difference between the MA and NM patients.
In agreement with other studies, 6,11 we did observe a higher incidence and earlier appearance of aGVHD following MA conditioning, which is commonly attributed to the tissue damage after the intensive conditioning. 12 Of note, all of the MA patients received high-dose (1200 cGy) TBI, which previously has been shown to be associated with more aGVHD as compared with BU. 13 The majority of the NM patients in our study received only 200 cGy TBI. Figure 4 . OS probability in patients in CR1 (left) and CR2 (right). Cumulative incidence of OS from myeloablative conditioning is depicted in black line with 95% confidence intervals shaded in dark grey and non-myeloablative conditioning in grey line with 95% confidence intervals shaded in light grey.
Outcome of MA and NM allogeneic HCT in AML patients H Sengeløv et al Although day 100 TRM was only 1.6 and 5.9% in CR1 and CR2 patients transplanted with NM conditioning, toxic deaths, typically from infections in relation to treatment of cGVHD occurred later in NM patients. Transplantation with an unrelated donor was a significant risk factor for TRM in CR1 patients, but it did not translate into a reduced OS in multivariable analysis.
Despite the use of a regimen with very low intensity, 8, 14 we observed relapse rates at 28.5 and 36.6% in CR1 and CR2 patients at 5 years after HCT, which was not statistically higher than the relapse rates in MA patients. Other single-centre studies have compared MA and NM transplants and reported relapse rates after NM HCT at 31-61%, [4] [5] [6] 15, 16 but patients in these studies were transplanted in more advanced disease stages, only 17-61% of the patients were in CR and observation time was shorter. Comparable relapse rates among MA and NM patients have been demonstrated in subgroup analyses of larger cohorts 6 and in a smaller group including MDS patients. 7 As chemosensitive AML in remission is the major indication for allogeneic HCT, 17 we found it important to analyse a homogenous group of AML patients in solid remission defined as o5% myeloblasts in the BM before transplant. The disease control in NM HCT has been shown to be dependent on tumour burden in other haematological diseases, 18 exemplified by inferior survival in lymphoma/CLL patients with bulky disease. 19, 20 Apparently, the impact of tumour burden also applies to AML and whilst NM conditioning may not be suitable for the advanced disease stages, patients in CR can benefit from disease control after this type of conditioning. Similar observations have been made in a multicentre study of 274 AML patients receiving NM transplants, where patients in remission had less relapse and better survival. 21 Our NM patients were relatively old and excellent survival in older patients in CR has also been reported from the MD Anderson Cancer Center. 22 As expected, bad cytogenetic profile was a risk factor for relapse in CR1 patients.
OS after NM conditioning has been evaluated in a large multicentre study from CIBMTR. 2 In that study, 52% of the patients were in CR1 or CR2 and a subset analysis of these patients showed a modest disease-free survival at 5 years of 26%, which was inferior to MA and reduced intensity conditioning patients. Centre experience is crucial in order to obtain good results, as highlighted in a recent study. 23 The CIBMTR study 2 analysed 407 NM patients from 85 centres from 1997 to 2004, while we report the outcome of 85 NM transplants performed from 2000 to 2010 in a single centre. Similar to our data, comparable OS in MA and NM transplants of AML patients in CR1 has recently been demonstrated in the prospective GOELAMS study, in which the OS at 108 months in 117 MA patients and 47 NM patients was 63,4% versus 65.8%, respectively. 24 Finally, a prospective, randomised study of patient aged 18-60 years with intermediate Figure 5 . Cumulative incidence (CI) of chronic GVHD (cGVHD) in CR1 patients (left) and CR2 patients (right). CI of cGVHD from myeloablative conditioning is depicted in black line with 95% confidence intervals shaded in dark grey, non-myeloablative conditioning in grey line with 95% confidence intervals shaded in light grey.
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